ReviewEndocrine pathology2005
The role of immunohistochemical markers in the diagnosis of follicular-patterned lesions of the thyroid.
Review in Endocrine pathology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 68 citations in OpenAlex.
- Article
- HBME1 and CK19 expression in non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) vs other follicular patterned thyroid lesions.World journal of surgical oncology · 2021Article
- The Intraoperative Immunohistochemical Staining of CD56 and CK19 Improves Surgical Decision for Thyroid Follicular Lesions.Journal of pathology and translational medicine · 2017Article
- [Thyroid-like follicular carcinoma of the kidney: a separate tumor entity?].Der Pathologe · 2014Article
- Cytokeratin19 expression discriminates papillary thyroid carcinoma from other thyroid lesions and predicts its aggressive behavior.Medical oncology (Northwood, London, England) · 2013Article
- Thyroid-like follicular carcinoma of the kidney with metastases to the lungs and retroperitoneal lymph nodes.Human pathology · 2011Article
- Serum Cyfra 21.1 and galectin-3 protein levels in relation to immunohistochemical cytokeratin 19 and galectin-3 expression in patients with thyroid tumors.Journal of cancer research and clinical oncology · 2010Article
- Nodal metastasis in well-differentiated follicular carcinoma of the thyroid: Its incidence and clinical significance.Oncology letters · 2010Article
- Cytological detection of papillary thyroid carcinomas by nuclear membrane decoration with emerin staining.Virchows Archiv : an international journal of pathology · 2010Article
- NDRG1 protein overexpression in malignant thyroid neoplasms.Clinics (Sao Paulo, Brazil) · 2010Article
- Oncocytes, oxyphils, Hürthle, and Askanazy cells: morphological and molecular features of oncocytic thyroid nodules.Endocrine pathology · 2010Review
- Discovery and identification of potential biomarkers of papillary thyroid carcinoma.Molecular cancer · 2009Article
- Differential expression of galectin-3, CK19, HBME1, and Ret oncoprotein in the diagnosis of thyroid neoplasms by fine needle aspiration biopsy.CytoJournal · 2009Article
- Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors.Endocrine pathology · 2009Article
- What is New on Thyroid Cancer Biomarkers.Biomarker insights · 2008Article
- Expression of cell cycle regulatory proteins in epithelial components of dental follicles.Journal of molecular histology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid nodules are extremely common in the general population. The differential diagnosis includes numerous entities, non-neoplastic and neoplastic, benign and malignant. However, the diagnosis of follicular-patterned lesions remains an area fraught with controversy and diagnostic criteria are highly variable. It is, therefore, a field in need of objective, scientific markers that better characterize these lesions than has been possible by classical morphology. A number of candidates have been proposed. No single marker can identify all malignant follicular-patterned lesions, however, various combinations have been proposed. They include HBME-1, high molecular weight cytokeratins and ret, galectin-3 and TPO, galectin-3, fibronectin-1, CITED-1, HBME-1, and CK19. Advances in our understanding of the molecular basis of thyroid cancer will allow the identification of new markers and more accurate characterization of specific subtypes of neoplasia and malignancy. As new markers are characterized and validated, directed by molecular profiling of thyroid lesions with characteristic morphology, behavior, and outcome, they will become available as routine immunohistochemical markers that will provide a more accurate, scientific, and clinically relevant consultation report from the pathologist for cytology and surgical pathology procedures. Application of these markers will enhance the diagnosis of thyroid nodules and better guide the management of patients with these lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.